SVF
Level A· Stronger Clinical EvidenceSystematic Review

Adipose-Derived Stem Cells in Traumatic Brain Injury: A Systematic Review of Preclinical Studies.

Ferreira MY., Paleare LFF., Silva YP., Lobo K., Cardoso LJC., Fukunaga CK.

Systematic Review on Neuroinflammation, published in Tissue Eng Regen Med (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Systematic Review
Journal
Tissue Eng Regen Med (2026)
Country
Korea (South)
Reported sample size
—
PMID
41511677
DOI
10.1007/s13770-025-00787-w

Abstract (original English)

Although traumatic brain injury (TBI) is a significant cause of morbidity and mortality worldwide, there have been few significant therapeutic advances in recent years. Preclinical studies have explored the potential of adipose-derived stem cells (ADSCs) to improve neural function and reduce brain damage in animal models following TBI. This systematic review aims to assess and synthesize the current evidence on the efficacy of ADSCs in animal models with induced TBI. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we systematically searched Scopus, PubMed, Web of Science, and Cochrane Library from inception to July 7, 2024, for original, English-language studies on animal models of induced TBI treated with ADSCs. We excluded in vitro, in silico, studies involving humans, and conference abstracts. Risk of bias was assessed using the Systematic Review Centre for Laboratory Animal Experimentation (SYRCLE) tool. Twenty-two studies met the inclusion criteria. The most common routes of ADSC administration were intravenous and intracerebral injections, typically given within 24 h of induced TBI. Histological and neuroimaging assessments showed reduced tissue swelling and interstitial fluid accumulation in ADSC-treated animals, indicating decreased brain vasogenic edema. ADSC treatment also reduced neuroinflammation markers, suggest

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
Brain Injuries, TraumaticAnimalsAdipose TissueHumansDisease Models, AnimalStem Cell TransplantationStem Cells
HipSystemic / IVNeuroinflammation
View on PubMedDOI

Related research